Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression

A. John Rush, Madhukar H. Trivedi, Stephen R. Wisniewski, Jonathan W. Stewart, Andrew A. Nierenberg, Michael E. Thase, Louise Ritz, Melanie M. Biggs, Diane Warden, James F. Luther, Kathy Shores-Wilson, George Niederehe, Maurizio Fava

Research output: Contribution to journalArticle

745 Citations (Scopus)

Abstract

Background: After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another. Methods: We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care settings. The primary outcome was symptom remission, defined by a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of the study. Scores on the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR-16), obtained at treatment visits, determined secondary outcomes, including remission (a score of 5 or less at exit) and response (a reduction of 50 percent or more on baseline scores). Results: Remission rates as assessed by the HRSD-17 and the QIDS-SR-16, respectively, were 21.3 percent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline, and 24.8 percent and 25.0 percent for extended-release venlafaxine. QIDS-SR-16 response rates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent for extended-release venlafaxine. These treatments did not differ significantly with respect to outcomes, tolerability, or adverse events. Conclusions: After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant. Any one of the medications in the study provided a reasonable second-step choice for patients with depression. (ClinicalTrials.gov number, NCT00021528).

Original languageEnglish (US)
Pages (from-to)1231-1242
Number of pages12
JournalNew England Journal of Medicine
Volume354
Issue number12
DOIs
StatePublished - Mar 23 2006

Fingerprint

Bupropion
Sertraline
Depression
Serotonin Uptake Inhibitors
Antidepressive Agents
Citalopram
Major Depressive Disorder
Therapeutics
Self Report
Psychiatry
Outpatients
Venlafaxine Hydrochloride
Equipment and Supplies
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., ... Fava, M. (2006). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine, 354(12), 1231-1242. https://doi.org/10.1056/NEJMoa052963

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. / Rush, A. John; Trivedi, Madhukar H.; Wisniewski, Stephen R.; Stewart, Jonathan W.; Nierenberg, Andrew A.; Thase, Michael E.; Ritz, Louise; Biggs, Melanie M.; Warden, Diane; Luther, James F.; Shores-Wilson, Kathy; Niederehe, George; Fava, Maurizio.

In: New England Journal of Medicine, Vol. 354, No. 12, 23.03.2006, p. 1231-1242.

Research output: Contribution to journalArticle

Rush, AJ, Trivedi, MH, Wisniewski, SR, Stewart, JW, Nierenberg, AA, Thase, ME, Ritz, L, Biggs, MM, Warden, D, Luther, JF, Shores-Wilson, K, Niederehe, G & Fava, M 2006, 'Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression', New England Journal of Medicine, vol. 354, no. 12, pp. 1231-1242. https://doi.org/10.1056/NEJMoa052963
Rush, A. John ; Trivedi, Madhukar H. ; Wisniewski, Stephen R. ; Stewart, Jonathan W. ; Nierenberg, Andrew A. ; Thase, Michael E. ; Ritz, Louise ; Biggs, Melanie M. ; Warden, Diane ; Luther, James F. ; Shores-Wilson, Kathy ; Niederehe, George ; Fava, Maurizio. / Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. In: New England Journal of Medicine. 2006 ; Vol. 354, No. 12. pp. 1231-1242.
@article{960033ea0c7a4476b95c5cc3972be5ad,
title = "Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression",
abstract = "Background: After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another. Methods: We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care settings. The primary outcome was symptom remission, defined by a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of the study. Scores on the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR-16), obtained at treatment visits, determined secondary outcomes, including remission (a score of 5 or less at exit) and response (a reduction of 50 percent or more on baseline scores). Results: Remission rates as assessed by the HRSD-17 and the QIDS-SR-16, respectively, were 21.3 percent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline, and 24.8 percent and 25.0 percent for extended-release venlafaxine. QIDS-SR-16 response rates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent for extended-release venlafaxine. These treatments did not differ significantly with respect to outcomes, tolerability, or adverse events. Conclusions: After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant. Any one of the medications in the study provided a reasonable second-step choice for patients with depression. (ClinicalTrials.gov number, NCT00021528).",
author = "Rush, {A. John} and Trivedi, {Madhukar H.} and Wisniewski, {Stephen R.} and Stewart, {Jonathan W.} and Nierenberg, {Andrew A.} and Thase, {Michael E.} and Louise Ritz and Biggs, {Melanie M.} and Diane Warden and Luther, {James F.} and Kathy Shores-Wilson and George Niederehe and Maurizio Fava",
year = "2006",
month = "3",
day = "23",
doi = "10.1056/NEJMoa052963",
language = "English (US)",
volume = "354",
pages = "1231--1242",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "12",

}

TY - JOUR

T1 - Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression

AU - Rush, A. John

AU - Trivedi, Madhukar H.

AU - Wisniewski, Stephen R.

AU - Stewart, Jonathan W.

AU - Nierenberg, Andrew A.

AU - Thase, Michael E.

AU - Ritz, Louise

AU - Biggs, Melanie M.

AU - Warden, Diane

AU - Luther, James F.

AU - Shores-Wilson, Kathy

AU - Niederehe, George

AU - Fava, Maurizio

PY - 2006/3/23

Y1 - 2006/3/23

N2 - Background: After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another. Methods: We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care settings. The primary outcome was symptom remission, defined by a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of the study. Scores on the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR-16), obtained at treatment visits, determined secondary outcomes, including remission (a score of 5 or less at exit) and response (a reduction of 50 percent or more on baseline scores). Results: Remission rates as assessed by the HRSD-17 and the QIDS-SR-16, respectively, were 21.3 percent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline, and 24.8 percent and 25.0 percent for extended-release venlafaxine. QIDS-SR-16 response rates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent for extended-release venlafaxine. These treatments did not differ significantly with respect to outcomes, tolerability, or adverse events. Conclusions: After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant. Any one of the medications in the study provided a reasonable second-step choice for patients with depression. (ClinicalTrials.gov number, NCT00021528).

AB - Background: After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another. Methods: We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care settings. The primary outcome was symptom remission, defined by a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of the study. Scores on the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR-16), obtained at treatment visits, determined secondary outcomes, including remission (a score of 5 or less at exit) and response (a reduction of 50 percent or more on baseline scores). Results: Remission rates as assessed by the HRSD-17 and the QIDS-SR-16, respectively, were 21.3 percent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline, and 24.8 percent and 25.0 percent for extended-release venlafaxine. QIDS-SR-16 response rates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent for extended-release venlafaxine. These treatments did not differ significantly with respect to outcomes, tolerability, or adverse events. Conclusions: After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant. Any one of the medications in the study provided a reasonable second-step choice for patients with depression. (ClinicalTrials.gov number, NCT00021528).

UR - http://www.scopus.com/inward/record.url?scp=33645098370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645098370&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa052963

DO - 10.1056/NEJMoa052963

M3 - Article

C2 - 16554525

AN - SCOPUS:33645098370

VL - 354

SP - 1231

EP - 1242

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 12

ER -